Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma

Lung Cancer

Volumn 82, Issue 3, 2013, Pages 491-498

  Creaney, Jenette ^a,b   Dick, Ian M ^a   Segal, Amanda ^c   Musk, Arthur W ^a,b,d   Robinson, Bruce W S ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c PATHWEST LABORATORY MEDICINE   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Diagnosis; Hyaluronic acid; Mesothelin; Mesothelioma; Pleural effusion

Indexed keywords

HYALURONIC ACID; MESOTHELIN;

AGED; ARTICLE; BLOOD LEVEL; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HYALURONIC ACID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; SURVIVAL TIME;

DIAGNOSIS; HYALURONIC ACID; MESOTHELIN; MESOTHELIOMA; PLEURAL EFFUSION;

AGED; FEMALE; GPI-LINKED PROTEINS; HUMANS; HYALURONIC ACID; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL CAVITY; PLEURAL EFFUSION; PLEURAL NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84887617176     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.09.016     Document Type: Article

References (44)

1. Robinson B.W., Musk A.W., Lake R.A. Malignant mesothelioma. Lancet 2005, 366:397-408.
2. Robinson B.W.S., Lake R.A. Advances in malignant mesothelioma. N Engl J Med 2005, 353:1591-1603.
3. Roboz J., Greaves J., Silides D., Chahinian A.P., Holland J.F. Hyaluronic acid content of effusions as a diagnostic aid for malignant mesothelioma. Cancer Res 1985, 45:1850-1854.
4. Pettersson T., Froseth B., Riska H., Klockars M. Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma. Chest 1988, 94:1037-1039.
5. Atagi S., Ogawara M., Kawahara M., Sakatani M., Furuse K., Ueda E., et al. Utility of hyaluronic acid in pleural fluid for differential diagnosis of pleural effusions: likelihood ratios for malignant mesothelioma. Jpn J Clin Oncol 1997, 27:293-297.
6. Welker L., Muller M., Holz O., Vollmer E., Magnussen H., Jorres R.A. Cytological diagnosis of malignant mesothelioma - improvement by additional analysis of hyaluronic acid in pleural effusions. Virchows Arch 2007, 450:455-461.
7. Grigoriu B., Chahine B., Zerimech F., Grégoire M., Balduyck M., Copin M.-C., et al. Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. Clin Biochem 2009, 42:1046-1050.
8. Hirose Y., Saijou E., Sugano Y., Takeshita F., Nishimura S., Nonaka H., et al. Inhibition of stabilin-2 elevates circulating hyaluronic acid levels and prevents tumor metastasis. Proc Natl Acad Sci U S A 2012, 109:4263-4268.
9. Fraser J.R., Laurent T.C., Pertoft H., Baxter E. Plasma clearance, tissue distribution and metabolism of hyaluronic acid injected intravenously in the rabbit. Biochem J 1981, 200:415-424.
10. Fraser J.R., Laurent T.C., Engstrom-Laurent A., Laurent U.G. Elimination of hyaluronic acid from the blood stream in the human. Clin Exp Pharmacol Physiol 1984, 11:17-25.
11. Robinson B.W.S., Creaney J., Lake R., Nowak A., Musk A.W., de Klerk N., et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003, 362:1612-1616.
12. Creaney J., Yeoman D., Naumoff L.K., Hof M., Segal A., Musk A.W., et al. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 2007, 62:569-576.
13. Hollevoet K., Reitsma J.B., Creaney J., Grigoriu B.D., Robinson B.W., Scherpereel A., et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 2012, 30:1541-1549.
14. Thylen A., Hjerpe A., Martensson G. Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma. Cancer 2001, 92:1224-1230.
15. Thylen A., Wallin J., Martensson G. Hyaluronan in serum as an indicator of progressive disease in hyaluronan-producing malignant mesothelioma. Cancer 1999, 86:2000-2005.
16. Martínez S.M., Crespo G., Navasa M., Forns X. Noninvasive assessment of liver fibrosis. Hepatology 2011, 53:325-335.
17. Light R.W., Macgregor M.I., Luchsinger P.C., Ball W.C. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med 1972, 77:507-513.
18. Whitaker D., Shilkin K. Diagnosis of pleural malignant mesothelioma in life - a practical approach. J Pathol 1984, 143:147-175.
19. Whitaker D., Sterrett G., Shilkin K. Cytological appearances of malignant mesothelioma. Malignant mesothelioma 1992, 167-182. Hemisphere, New York. D. Henderson, K. Shilkin, S. Langlois, P. Le, D. Whitaker (Eds.).
20. Segal A., Sterrett G.F., Frost F.A., Shilkin K.B., Olsen N.J., Musk A.W., et al. A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit. Pathology 2013, 45:44-48.
21. Creaney J., Olsen N.J., Brims F., Dick I.M., Musk A.W., de Klerk N.H., et al. Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. Cancer Epidemiol Biomarkers Prev 2010, 19:2238-2246.
22. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
23. National Kidney Foundation Evaluation, classification, and stratification 2009, The National Kidney Foundation Disease Outcomes Quality Initiative (NKF KDOQI)™.
24. Boudville N., Paul R., Robinson B.W.S., Creaney J. Mesothelin and kidney function - analysis of relationship and implications for mesothelioma screening. Lung Cancer 2011, 73:320-324.
25. Davies H.E., Sadler R.S., Bielsa S., Maskell N.A., Rahman N.M., Davies R.J., et al. Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. Am J Respir Crit Care Med 2009, 180:437-444.
26. Scherpereel A., Grigoriu B.D., Conti M., Gey T., Gregoire M., Copin M.C., et al. Soluble mesothelin-related protein in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006, 173:1155-1160.
27. Yamada S., Tabata C., Tabata R., Fukuoka K., Nakano T. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma. Clin Chem Lab Med 2011, 49:1721-1726.
28. Adams L.A. Biomarkers of liver fibrosis. J Gastroenterol Hepatol 2011, 26:802-809.
29. Hollevoet K., Bernard D., De Geeter F., Walgraeve N., Van den Eeckhaut A., Vanholder R., et al. Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum. Clin Chem 2009, 55:1431-1433.
30. Zaga T., Makris D., Tsilioni I., Kiropoulos T., Oikonomidi S., Damianos A., et al. Hyaluronic acid levels are increased in complicated parapneumonic pleural effusions. Monaldi Arch Chest Dis 2011, 75:167-171.
31. Josefsson A., Adamo H., Hammarsten P., Granfors T., Stattin P., Egevad L., et al. Prostate cancer increases hyaluronan in surrounding nonmalignant stroma, and this response is associated with tumor growth and an unfavorable outcome. Am J Pathol 2011, 179:1961-1968.
32. Ghatak S., Hascall V.C., Markwald R.R., Misra S. Stromal hyaluronan interaction with epithelial CD44 variants promotes prostate cancer invasiveness by augmenting expression and function of hepatocyte growth factor and androgen receptor. J Biol Chem 2010, 285:19821-19832.
33. Jang B.I., Li Y., Graham D.Y., Cen P. The role of CD44 in the pathogenesis, diagnosis, and therapy of gastric cancer. Gut Liver 2011, 5:397-405.
34. Misra S., Hascall V.C., Berger F.G., Markwald R.R., Ghatak S. Hyaluronan, CD44, and cyclooxygenase-2 in colon cancer. Connect Tissue Res 2008, 49:219-224.
35. Montgomery N., Hill A., McFarlane S., Neisen J., O'Grady A., Conlon S., et al. CD44 enhances invasion of basal-like breast cancer cells by up-regulating serine protease and collagen-degrading enzymatic expression and activity. Breast Cancer Res 2012, 14. R84.
36. Tammi R.H., Kultti A., Kosma V.-M., Pirinen R., Auvinen P., Tammi M.I. Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan. Semin Cancer Biol 2008, 18:288-295.
37. Toole B.P. Hyaluronan-CD44 interactions in cancer: paradoxes and possibilities. Clin Cancer Res 2009, 15:7462-7468.
38. Kwee W.S., Veldhuizen R.W., Golding R.P., Mullink H., Stam J., Donner R., et al. Histologic distinction between malignant mesothelioma, benign pleural lesion and carcinoma metastasis. Evaluation of the application of morphometry combined with histochemistry and immunostaining. Virchows Arch A Pathol Anat Histol 1982, 397:287-299.
39. Afify A.M., Stern R., Michael C.W. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization. Diagn Cytopathol 2005, 32:145-150.
40. Jones L.M.H., Gardner M.J., Catterall J.B., Turner G.A. Hyaluronic acid secreted by mesothelial cells: a natural barrier to ovarian cancer cell adhesion. Clin Exp Metastasis 1995, 13:373-380.
41. Tamada Y., Takeuchi H., Suzuki N., Aoki D., Irimura T. Cell surface expression of hyaluronan on human ovarian cancer cells inversely correlates with their adhesion to peritoneal mesothelial cells. Tumour Biol 2012, 33:1215-1222.
42. Stern R., Asari A.A., Sugahara K.N. Hyaluronan fragments: an information-rich system. Eur J Cell Biol 2006, 85:699-715.
43. Fujimoto N., Gemba K., Asano M., Fuchimoto Y., Wada S., Ono K., et al. Hyaluronic acid in the pleural fluid of patients with malignant pleural mesothelioma. Respir Investig 2013, 51:92-97.
44. Trape J., Molina R., Sant F. Clinical evaluation of the simultaneous determination of tumor markers in fluid and serum and their ratio in the differential diagnosis of serous effusions. Tumour Biol 2004, 25:276-281.